Ionis Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
Stock Snapshot
As of today, Ionis Pharmaceuticals(IONS) shares are valued at $73.28. The company's market cap stands at 12.11B, with a P/E ratio of -34.86.
During the trading session on 2026-06-14, Ionis Pharmaceuticals(IONS) shares reached a daily high of $74.39 and a low of $72.58. At a current price of $73.28, the stock is +1.0% higher than the low and still -1.5% under the high.
Trading activity shows a volume of 1.84M, compared to an average daily volume of 1.71M.
The stock's 52-week range extends from a low of $34.78 to a high of $86.74.
The stock's 52-week range extends from a low of $34.78 to a high of $86.74.
IONS News
Ionis Pharmaceuticals ( (IONS) ) has provided an update. On June 12, 2026, Ionis Pharmaceuticals reported positive new data from its CORE-OLE open-label extens...
Ionis Pharmaceuticals (NasdaqGS:IONS) has appointed Ludwig Hantson, Ph.D. to its Board of Directors. Dr. Hantson brings decades of global biopharmaceutical lea...
Ionis Pharmaceuticals ( (IONS) ) just unveiled an update. Ionis Pharmaceuticals on June 4, 2026, appointed veteran biopharmaceutical executive Ludwig Hantson,...
Analyst ratings
89%
of 27 ratingsMore IONS News
Ionis Pharmaceuticals (IONS) announced the appointment of Ludwig Hantson, Ph.D. to the Ionis Board of Directors, effective immediately. Before joining Alexion,...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.